Metabolic Consequences of Moderate Weight Gain - Role of Dietary Fat Composition (LIPOGAIN)

Not Applicable

Completed

• Conditions: Healthy

• Registration Number: NCT01427140
• Lead Sponsor: Uppsala University

Brief Summary

The purpose of this study is to investigate the metabolic consequences of a moderate weight gain and if the type of dietary fat (saturated versus polyunsaturated) can modify the effects in young healthy adults. Hypothesis: the type of dietary fat can modify the effects of weight gain.

Detailed Description

Specific goals:

* Investigate if dietary fat composition influences liver fat accumulation and metabolic risk factors in response to moderate weight gain

* Investigate if polyunsaturated fat (PUFA) in the diet could counteract any unfavorable metabolic changes that are expected to accompany moderate weight gain

* Investigate effects of weight gain and dietary fat composition on markers of vascular health

Study Timeline

• Study First Submitted: 2011-08-19
• Study First Submitted QC: 2011-08-31
• Study Start: 2011-09
• Study First Posted: 2011-09-01
• Status Verified: 2011-12
• Primary Completion: 2011-12
• Study Completion: 2011-12
• Last Update Submitted: 2011-12-08
• Last Update Posted: 2011-12-09

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 41

Inclusion Criteria

• Healthy,
• Body Mass Index 18-27

Exclusion Criteria

• Liver disease,
• Coronary heart disease,
• Diabetes mellitus,
• Malignant diseases,
• Alcohol or drug abuse,
• Magnetic Resonance-incompatibility,
• Abnormal clinical chemistry,
• Use of drugs that significantly effects energy metabolism,
• Heavy exercise,
• Pregnancy or lactation,
• Allergy of gluten, egg or milk protein

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
Hepatic steatosis by magnetic resonance tomography (MRT)	6 weeks

Secondary Outcome Measures

Name	Time	Method
Triglycerides	6 weeks
Cholesterol	6 weeks
Apolipoprotein B (ApoB)	6 weeks
high density lipoprotein (HDL)	6 weeks
low density lipoprotein (LDL)	6 weeks
Insulin	6 weeks
Glucose	6 weeks
Apolipoprotein A1 (ApoA1)	6 weeks
Aspartate aminotransferase (ASAT)	6 weeks
Alanine aminotransferase (ALAT)	6 weeks
Gamma glutamyl transpeptidase (GGT)	6 weeks
Homeostasis model of assessment insulin resistance (HOMA-IR)	6 weeks
C-reactive protein (CRP)	6 weeks
Proinsulin	6 weeks
Endostatin	6 weeks
Pentraxin-3 (PTX-3)	6 weeks
Endothelin-1 (ET-1)	6 weeks
E-selectin	6 weeks
Cathepsin-S	6 weeks
Cystatin C	6 weeks

Trial Locations

Locations (1)

Uppsala University Hospital, Uppsala Science Park; 🇸🇪 Uppsala, Sweden